BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Link Technologies Ltd Improves Oligonucleotides for Use in Research and Diagnostics


9/26/2011 10:35:20 AM

BELLSHILL, SCOTLAND, 26 September 2011: Link Technologies Ltd, an ISO 9001:2008 certified specialist oligonucleotide reagent manufacturer, recently presented the latest results from its in-house research programme at the Cambridge Symposium on Nucleic Acids Chemistry and Biology, (CSNACB), UK, 4-7 September 2011. The new poster describes methods for utilising tocopherol-modified oligos, which improve the targeting of oligonucleotides to cells. In this study, the researchers also took advantage of the high hydrophobicity of tocopherol to improve the purification of thiol-modified oligos. The poster is now available to download from the Link Technologies website. Such efforts are part of the company’s continuing commitment to driving forward the application of oligonucleotides in research, diagnostics and therapeutics.

Link Technologies’ research and development team includes highly qualified chemists and application specialists, whose extensive expertise covers the synthesis, modification and application of oligonucleotides. As well as the research presented at the CSNACB, Link Technologies’ scientists have also been investigating novel ways to improve the internal labelling of oligonucleotides with dyes, haptens and enzymes via thiol-modification. Until now, simple thiol-modification has been limited to the ends of an oligo. However, the researchers are currently optimising the use of a new product that facilitates direct incorporation of the thiol functionality on a dT unit, allowing conjugation of the oligo without further transformation. To allow customers to access this data, as well as that from other projects, Link provides a range of download links and extra information via its website.

Dr Catherine McKeen, Product Manager at Link Technologies, commented: “At Link Technologies we don't just sell reagents for oligonucleotide synthesis; we commit considerable time, resources and expertise to making sure we understand them better than anyone else. This ethos stretches throughout the company and is especially emphasised by the quality of the scientific research we present at meetings such as the CSNACB.” The company’s extensive product catalogue includes reagents for DNA, RNA, PNA & UNA synthesis and modification. In addition, Link offers fully bespoke custom synthesis and contract manufacturing services, all of which utilise an ISO 9001:2008 certified quality management system, rigorous quality control (QC) procedures and pro-active delivery tracking systems to maximise the accuracy and efficiency of the service provided.

Follow @linktechdna on Twitter for all the latest news. More information can also be found by reading the latest Link Technologies blog post or by visiting the company’s website.

About Link Technologies Ltd

Link Technologies Ltd is a leading kilo-scale supplier of speciality reagents for oligonucleotide synthesis and modification, all to the ISO 9001:2008 quality certification. The company’s main markets are university and commercial research departments, plus, increasingly, larger Contract Manufacturing Organisations (CMOs) in the biotech sector. Link has also forged successful links to academia working closely with many UK universities. In tandem with internal research and development, the Company has an excellent record in bringing in-licence products to market with various worldwide commercial partners.

For further information see: www.linktech.co.uk



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES